Back
 

View:
Mini 
BasicThis view is available after user registration.
 
ShortThis view is available when you buy a license.
 
StandardThis view is available when you buy a license.
 
CompleteThis view is available when you buy a license.
 

Study - CELESTIMO - Rituximab 375 / Lenalidomide 20, Follicular Lymphoma grade I-IIIa, cycle 1

Protocol-ID: 2077 V1.0 (Mini), STUDY - CELESTIMO - RITU375/LENA20, foll. Lymphoma °I-IIIa, C1
Study protocol, available to authorized participants only.

Indication(s)

  • NHL, B-Cell Type, Follicular Grade I-IIIa; ICD-10 C82.9
The publishers and authors assume no liability for the accuracy of the contents. The application is at the own responsibility of the treating physician. ©Onkopti.

Valid since: 31.05.2022